Galapagos NV
AEX:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
AEX:GLPG
Watchlist
Price: 26.24 EUR 1.23% Market Closed
Market Cap: 1.7B EUR
Have any thoughts about
Galapagos NV?
Write Note

EV/EBIT
Enterprise Value to EBIT

7.9
Current
9.4
Median
4
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
7.9
=
Enterprise Value
-1.7B EUR
/
EBIT
-213.9m EUR
All Countries
Close
Market Cap EV/EBIT
BE
Galapagos NV
AEX:GLPG
1.7B EUR 7.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 130
US
Abbvie Inc
NYSE:ABBV
314.6B USD 23.7
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 30.3
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD 22.8
US
Epizyme Inc
F:EPE
94.1B EUR -500.7
AU
CSL Ltd
ASX:CSL
136.4B AUD 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 17
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
36.2B EUR -80.2
EBIT Growth EV/EBIT to Growth
BE
Galapagos NV
AEX:GLPG
Average EV/EBIT: 19.6
7.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 130 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.3
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.7 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.2 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
14.4
2-Years Forward
EV/EBIT
10.4
3-Years Forward
EV/EBIT
9.9

See Also

Discover More